Suppr超能文献

基于日本基于人群的癌症登记数据的 1993-2006 年小细胞肺癌生存趋势。

Trends in Small-Cell Lung Cancer Survival in 1993-2006 Based on Population-Based Cancer Registry Data in Japan.

机构信息

Division of Cancer Epidemiology and Prevention, Department of Preventive Medicine, Aichi Cancer Center Research Institute.

Division of Cancer Information and Control, Department of Preventive Medicine, Aichi Cancer Center Research Institute.

出版信息

J Epidemiol. 2019 Sep 5;29(9):347-353. doi: 10.2188/jea.JE20180112. Epub 2018 Nov 17.

Abstract

BACKGROUND

Lung cancers are classified into small-cell lung cancer (SCLC) and non-small-cell lung cancer due to their different treatment and prognosis. Although many studies have reported the specific survival of SCLC patients treated at cancer hospitals, survival from population-based data has rarely been reported.

METHODS

We analyzed survival of SCLC cases diagnosed from 1993 through 2006 from a population-based cancer registry of six prefectures. To assess trends in SCLC survival, we defined three periods that mirrored developments in SCLC treatment: period 1, 1993-1998; period 2, 1999-2001; and period 3, 2002-2006. Assessments were based on relative survival (RS), excess hazard, and conditional survival.

RESULTS

A total of 10,911 SCLC patients were analyzed. Five-year RS among limited disease SCLC (LD-SCLC) in periods 1 to 3 was 16.8%, 21.1%, and 21.4%, respectively. Five-year RS among extensive disease SCLC (ED-SCLC) in periods 1 to 3 was 2.3%, 2.8%, and 2.7%, respectively. Improvement in 5-year RS in periods 2 and 3 compared with period 1 was significant among both LD- and ED-SCLC patients (all P < 0.001). Conditional 5-year RS of LD-SCLC increased from 21% at year 0 to 73% at year 5, while that of ED-SCLC was 3% at year 0 and 53% at year 5.

CONCLUSIONS

The prognosis of SCLC patients improved from 1999-2001 but plateaued in 2002-2006, after which no further significant improvement was seen. Continuous survey based on population-based data is helpful in monitoring the impact of developments in treatment.

摘要

背景

肺癌因其治疗和预后的不同,被分为小细胞肺癌(SCLC)和非小细胞肺癌。虽然许多研究报告了癌症专科医院治疗的 SCLC 患者的特定生存率,但基于人群的数据很少有报道。

方法

我们分析了 1993 年至 2006 年期间,来自六个县的基于人群的癌症登记处诊断出的 SCLC 病例的生存情况。为了评估 SCLC 生存趋势,我们定义了三个反映 SCLC 治疗进展的时期:时期 1,1993-1998 年;时期 2,1999-2001 年;时期 3,2002-2006 年。评估基于相对生存率(RS)、超额风险和条件生存率。

结果

共分析了 10911 例 SCLC 患者。局限期 SCLC(LD-SCLC)在时期 1 至 3 的 5 年 RS 分别为 16.8%、21.1%和 21.4%。广泛期 SCLC(ED-SCLC)在时期 1 至 3 的 5 年 RS 分别为 2.3%、2.8%和 2.7%。与时期 1 相比,时期 2 和 3 的 LD-SCLC 和 ED-SCLC 患者的 5 年 RS 改善均有统计学意义(均 P < 0.001)。LD-SCLC 的 5 年条件 RS 从 0 年的 21%增加到 5 年的 73%,而 ED-SCLC 的 RS 从 0 年的 3%增加到 5 年的 53%。

结论

SCLC 患者的预后从 1999-2001 年开始改善,但在 2002-2006 年趋于稳定,此后未再出现显著改善。基于人群的连续监测有助于监测治疗进展的影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/921f/6680055/e2dfc60ec307/je-29-347-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验